61958-2002 : Descovy Oral Tablet

Labeler: Gilead Sciences, Inc.
Product Type: Human Prescription Drug
Drug Name:  Descovy
Dosage Form: Oral Tablet
Application #: NDA208215
Rev. Date: 


Markings: GSI;255
Shapes:  Oval
Colors:  Blue
Size (mm): 13
Segments: * 1

* Segments = the number of equally sized pieces which the pill can be broken into. In this case, a value of 1 indicates a solid pill with no score lines.

NDC Package Codes:

  • 61958-2002-1: 30 TABLET IN 1 BOTTLE, PLASTIC (61958‑2002‑1)
  • 61958-2002-2: 30 TABLET IN 1 BLISTER PACK (61958‑2002‑2)

Active Ingredients:

  • Emtricitabine
  • Tenofovir Alafenamide Fumarate

Dosage Strength:

  • 200 mg
  • 25 mg

Inactive Ingredients:

  • Microcrystalline Cellulose
  • Croscarmellose Sodium
  • Magnesium Stearate
  • Water
  • Polyvinyl Alcohol, Unspecified
  • Titanium Dioxide
  • Polyethylene Glycol 3350
  • Talc
  • Fd&c Blue No. 2

Pharmaceutical Classes:

  • Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
  • Nucleoside Analog [Chemical/Ingredient]
  • Nucleoside Reverse Transcriptase Inhibitors [MoA]
  • Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

Related Products:

Based on records with the same trade name.
  • 61958-2005 Descovy Oral Tablet by Gilead Sciences, Inc.
  • 70518-0230 Descovy Oral Tablet by Remedyrepack Inc.


Scan the QR code below to easily reference this data in the future:

NDC 61958-2002 QR Code

< Prev: 61958-1901Next: 61958-2005 >

Related Discussions:

Tenofovir with primolut N
Actually I am taking tenofovir from the past 2 years. Now I need to take primolut N. Can I take it with tenofovir? One o...

Note: The MedsChat® NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.